News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
700,667 Results
Type
Article (41576)
Company Profile (463)
Press Release (658628)
Section
Business (208386)
Career Advice (2002)
Deals (35941)
Drug Delivery (92)
Drug Development (83290)
Employer Resources (169)
FDA (16325)
Job Trends (15043)
News (352064)
Policy (32976)
Tag
Academia (2619)
Alliances (50589)
Alzheimer's disease (1270)
Approvals (16248)
Artificial intelligence (135)
Bankruptcy (361)
Best Places to Work (11728)
Biotechnology (349)
Breast cancer (121)
Cancer (1081)
Cardiovascular disease (96)
Career advice (1671)
Cell therapy (243)
Clinical research (65921)
Collaboration (390)
Compensation (193)
COVID-19 (2588)
C-suite (93)
Data (1089)
Diabetes (155)
Diagnostics (6191)
Earnings (86029)
Employer resources (147)
Events (112833)
Executive appointments (293)
FDA (16850)
Funding (347)
Gene therapy (189)
GLP-1 (608)
Government (4407)
Healthcare (18990)
Infectious disease (2670)
Inflammatory bowel disease (111)
Interviews (308)
IPO (16562)
Job creations (3694)
Job search strategy (1428)
Layoffs (439)
Legal (7926)
Lung cancer (171)
Manufacturing (176)
Medical device (13318)
Medtech (13323)
Mergers & acquisitions (19427)
Metabolic disorders (418)
Neuroscience (1544)
NextGen Class of 2024 (6733)
Non-profit (4531)
Northern California (1451)
Obesity (241)
Opinion (197)
Patents (99)
People (57575)
Phase I (20651)
Phase II (29097)
Phase III (21523)
Pipeline (449)
Postmarket research (2590)
Preclinical (8866)
Radiopharmaceuticals (251)
Rare diseases (224)
Real estate (5997)
Regulatory (21939)
Research institute (2403)
Resumes & cover letters (351)
Southern California (1296)
Startups (3746)
United States (13544)
Vaccines (564)
Weight loss (182)
Date
Today (164)
Last 7 days (967)
Last 30 days (3655)
Last 365 days (36634)
2024 (33242)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33024)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (199)
Asia (38486)
Australia (6397)
California (3319)
Canada (1272)
China (246)
Colorado (146)
Connecticut (154)
Europe (83930)
Florida (443)
Georgia (113)
Illinois (350)
Indiana (194)
Kansas (99)
Maryland (583)
Massachusetts (2670)
Michigan (155)
Minnesota (274)
New Jersey (946)
New York (948)
North Carolina (750)
Northern California (1451)
Ohio (137)
Pennsylvania (832)
South America (1105)
Southern California (1296)
Texas (458)
Utah (90)
Washington State (367)
700,667 Results for "xylocor therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions
XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions.
May 2, 2024
·
6 min read
Press Releases
XyloCor Therapeutics and SmartCella Enter into License Agreement for Use of the Extroducer Infusion Catheter System to Administer Novel Gene Therapy XC001 to the Heart
July 10, 2024
·
6 min read
Drug Development
XyloCor Therapeutics Presents Phase 2 Data Highlighting Safety and Efficacy of XC001 at the European Society of Cardiology (ESC) Congress 2023
XyloCor Therapeutics, Inc. presented results from the Phase 2 portion of its Phase 1/2 clinical trial of its lead gene therapy candidate XC001 for refractory angina at the European Society of Cardiology Congress 2023.
August 25, 2023
·
5 min read
Drug Development
Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions
Results from XyloCor Therapeutics’ Phase 1 Portion of EXACT Trial of XC001 for Cardiovascular Disease Published in Circulation: Cardiovascular Interventions.
August 3, 2023
·
5 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Drug Development
XyloCor Therapeutics Reports Sustained Results in 12-Month Extension of Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina
XyloCor Therapeutics, a clinical-stage biopharmaceutical company developing novel gene therapies for cardiovascular disease, today reported positive 12-month data from the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) designed to assess the safety and provide preliminary evidence of efficacy of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina.
July 18, 2023
·
5 min read
Drug Development
XyloCor Advances Cardiovascular Gene Therapy Space with Positive Angina Results
XyloCor Therapeutics reported positive topline results Thursday from Phase II of the Phase I/II trial of its gene therapy for refractory angina.
January 27, 2023
·
2 min read
·
Heather McKenzie
Drug Development
XyloCor Therapeutics Reports Positive Topline Safety and Efficacy Results from Phase 2 EXACT Clinical Trial of XC001 Novel Gene Therapy for Refractory Angina
XyloCor Therapeutics today announced completion of the Phase 2 portion of its Phase 1/2 clinical trial (EXACT) designed to assess the safety and preliminary evidence of efficacy of lead gene therapy candidate XC001 (encoberminogene rezmadenovec) in patients with refractory angina.
January 26, 2023
·
5 min read
Press Releases
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index
November 13, 2024
·
4 min read
Business
Gain Therapeutics, Inc. Appoints Gene Mack as Interim CEO
Gain Therapeutics, Inc. announces that Matthias Alder has departed the Company in order to pursue other opportunities.
June 27, 2024
·
5 min read
1 of 70,067
Next
